Further to Imagion Biosystems Limited’s announcement dated 23 May 2018, the Company advises of an amendment to Resolution 9 of its Notice of Annual General Meeting dated 2 May 2018, which is detailed in the attached Notice of Amendment.
Save for as detailed in the Notice of Amendment, which will shortly be despatched to shareholders, all other aspects of the Notice of Annual General Meeting remain unchanged.
The Company’s Annual General Meeting will be held at 1.30pm (AEST) on Thursday, 31 May 2018 at the offices of Holding Redlich, Level 8, 555 Bourke Street, Melbourne, Victoria 3000.
Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway
September 9, 2025
Highlights Dr Nina Webster appointed as IBX Non-Executive Director, bringing significant clinical development expertise and corporate experienceto the IBX Board ahead of HER2 Breast cancer